Perosphere is a private pharmaceutical company focused on addressing unmet medical needs associated with anticoagulant therapies
Perosphere's lead investigational drug product candidate, ciraparantag (PER977), is an intravenously administered small synthetic water soluble new molecular entity rationally designed by Perosphere for use as a broad-spectrum reversal agent for anticoagulants including heparins and the new oral anticoagulants (NOACs) allowing rapid re-establishment of a normal blood coagulation state when clinically indicated. The NOACs include Daiichi Sankyo Co., Ltd.'s SavaysaTM/Lixiana® (edoxaban), Boehringer Ingelheim GmbH's Pradaxa® (dabigatran), Johnson & Johnson's and Bayer HealthCare AG's Xarelto® (rivaroxaban), and Bristol-Myers Squibb Company's and Pfizer Inc.'s Eliquis® (apixaban). There is currently no approved broad-spectrum reversal agent for these NOACs. Ciraparantag is currently undergoing Phase 2 clinical trials in the United States.
The lead investigational device product candidate is Perosphere’s point-of-care coagulometer, a hand-held device that tests fresh or citrated whole blood. The system is designed for broad-spectrum monitoring of the activity of anticoagulants and their corresponding antidotes, across drug classes, in a hospital setting at a patient’s bedside. A single test requires only 10 microliters of fresh or citrated whole blood from a venous draw or finger stick. Test results are reported within minutes. The system employs single-use, proprietary test strips containing no anticoagulant-specific chemical or biological reagents.